This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
At the beginning of each year, we compile our sales hiring forecast by looking at the overall hiring forecasts for the year made by Manpower, Glassdoor, Indeed, Monster, and the Bureau of Labor & Statistics (BLS). 2021 Sales Hiring in Review. 2021 Sales Hiring in Review. 2022 Sales Forecast for Hiring.
Grünenthal is paying up to €500 million ($501 million) for rights to Nebido (testosterone undecanoate), which is sold in around 80 countries worldwide for testosterone deficiency and made sales of €117 million last year.
Medical sales can be a lucrative job , but it depends on a number of factors , including the specific products or services being sold, the company or industry sector, and the individual's sales performance. Additionally, the medical sales industry is expected to grow in the coming years.
Mounjaro’s approval for obesity, particularly in the US and EU markets, means the drug is entering a significantly large market where it will have direct competition from Novo Nordisk’s Wegovy (semaglutide), which is currently the leading glucagon-like peptide-1 (GLP-1) therapy approved for obesity by both the FDA and EMA.
per share deal includes $8 per share upfront, worth around $576 million, with the remainder in the form of a contingent value right (CVR) that will be paid to Concert shareholders if deuroxilitinib meets certain sales targets within a set time limit. The $11.50 The report predicts that the alopecia areata market will grow to as much as $2.5
Most seasoned medical sales representatives have carried several different products or services over their careers. Between emerging technologies, expiring patents, and ever-changing insurance coverage, the role of a medical sales professional is to constantly adapt and learn new things. Selling cutting-edge technology is exciting.
Furthermore, the organization predicts it will outpace the GDP by 2030. This is great news for those in medtech sales! And your reps need to adopt an omnichannel process that uses all of the medical device sales channels at their disposal. Each threatens to derail your medical device sales process in some way.
You need to optimize your company’s solar sales funnel. Of course, wanting to improve your solar sales process and actually doing it are different things. Understanding Solar Sales Before we discuss the various stages of the solar sales funnel, let’s zoom out and analyze the industry as a whole.
On the other hand, original manufacturers often face tough competition, as the market becomes flooded with alternatives. For pharma sales reps, this shift changes the conversation. It’s a dynamic that keeps the industry competitive and ensures patients benefit from a range of choices. million and is projected to reach $1,237.4
The bi-weekly intramuscular shot – which was also approved in China in 2021 – will enter a crowded market for long-acing injectable (LAI) schizophrenia therapies in the US and have to take on heavyweight competition, including drugs that require less frequent dosing.
billion in 2030 ). A buyer persona is a semi-fictional representation of your ideal customer based on sales data and industry research. Differentiating medical devices can be challenging due to commoditization and the fast pace of technological advances, but it’s critical to stand out in a competitive device market.
In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.
Merck has multibillion-collar sales expectations for sotatercept, which will be at the heart of a renewed push into cardiovascular disease therapies. .” “We are moving with urgency on our regulatory applications to bring this investigational therapy to these patients,” he added.
from 2022 to 2030, the pharma industry will reach USD 9,241.34 million by 2030. from 2023 to 2030. Pharma companies can utilize big data to predict the sale of a particular medicine owing to various demographic factors. Poised to grow at a CAGR of 29.4% The global pharmacovigilance (PV) market stood at USD 7.80
Lifted by increased interest after the onset of the Covid-19 pandemic, the sector is expected to balloon to US$853 billion by 2030. The US still dominates the biopharma sector with more than $378bn in annual drug sales and an approximate capacity of 30% of global manufacturing. City Competitiveness Index. ft2 in Toronto 1.
Pharma giant AstraZeneca also plans to make its supply chain carbon-negative by 2030; to reduce its Scope 1 emissions by 20%, Scope 2 emissions by 95%, and Scope 3 emissions by 25% per $1m of sales by 2025. In 2020, Fisher & Paykel Healthcare, a medical devices firm, made a SBTi commitment to reduce GHG emissions by 67% by 2034.
BioNTech is anticipated to lead the market with a predicted $885 million in sales, and a 44.6 billion by 2030 BioNTech Development of mRNA-based oncology therapies for German biotech BioNTech is progressing. OTX-2002 from Omega Therapeutics is an mRNA therapy anticipated to generate $658 million in global sales, representing 33.2
As competition intensifies, strategic marketing becomes the key differentiator, ensuring that companies not only survive but thrive. holds the largest share of the medical device market, accounting for over 40% of global sales. Understanding The MedTech Industry The MedTech industry is a global powerhouse, valued at over $629.5
With analysts estimating that obesity drug sales could top $100 billion annually , concerns over the financial hit is likely why plans covering 30% of lives do not reimburse Wegovy, per Clarivate Fingertip Analytics data. The arrival of a second drug may drive PBMs to expand coverage in exchange for aggressive rebates.
Prioritize Education Over Sales Older adults and seniors prefer unbiased education over high-pressure sales tactics to make informed decisions. Retaining loyal members requires a smart, tailored approach to stay competitive." In fact, some expectations will be 60% penetration by 2030, which is just five years away.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content